title: [Trabectedin (ET-743/Yondelis) for treating soft tissue sarcomas and ovarian cancer].
abstract: Soft tissue sarcomas account for 1% of all malignant tumours. Until a few years ago, doxorubicine and ifosfamide were the only active chemotherapy drugs in the metastatic setting. Recently, a new drug has proven its efficacy after failure of standard treatments: the trabectedin; its activity is based on interference with ADN repair mechanisms. Trabectedin has just been also validated and reimbursed in patients with ovarian cancer, in partially sensitive recurrence. In this paper, we will review the mechanism of action and the clinical results of trabectedin.
authors.affiliation: Service d'Oncologie Médicale, CHU de Liège, Belgique. christinegennigens@yahoo.com
authors.forename: C
authors.initials: C
authors.lastname: Gennigens
authors.forename: G
authors.initials: G
authors.lastname: Jerusalem
mesh_terms: D018906:Antineoplastic Agents, Alkylating / Q000494:pharmacology* / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D004149:Dioxoles / Q000494:pharmacology* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D010051:Ovarian Neoplasms / Q000188:drug therapy; D012509:Sarcoma / Q000188:drug therapy; D012983:Soft Tissue Neoplasms / Q000188:drug therapy; D044005:Tetrahydroisoquinolines / Q000494:pharmacology* / Q000627:therapeutic use; D000077606:Trabectedin
chemical_list: D018906:Antineoplastic Agents, Alkylating; D004149:Dioxoles; D044005:Tetrahydroisoquinolines; D000077606:Trabectedin